Keymed Biosciences Inc. (HKG:2162)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
75.25
-0.40 (-0.53%)
Apr 28, 2026, 4:08 PM HKT
78.11%
Market Cap 22.17B
Revenue (ttm) 797.12M
Net Income (ttm) -581.60M
Shares Out 294.60M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE 44.52
Dividend n/a
Ex-Dividend Date n/a
Volume 1,239,523
Average Volume 3,497,440
Open 72.15
Previous Close 75.65
Day's Range 72.15 - 78.30
52-Week Range 37.40 - 81.85
Beta -0.25
RSI 62.14
Earnings Date Mar 26, 2026

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodularis, and respiratory related indications. The company is also developing CMG901, a Claudin 18.2 antibody drug conjugate in Phase III trial to treat gas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,625
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2162
Full Company Profile

Financial Performance

In 2025, Keymed Biosciences's revenue was 716.31 million, an increase of 67.31% compared to the previous year's 428.12 million. Losses were -522.64 million, 1.44% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.